JWH-018

JWH-018 is an aminoalkylindole synthetic cannabinoid that transitioned from a laboratory probe to a notorious designer drug. Functional assays confirm it is a full agonist at both cannabinoid receptors, with nanomolar potency; in a comparison of synthetic cannabinoid designer drugs it activated human CB1 and CB2 receptors, and terminal fluorination of related indoles generally increased CB1 potency.

Unlike the partial agonist THC, JWH-018 behaves as a high-efficacy full agonist, which helps explain its greater potency and hazard. Its pharmacology is complicated by active metabolism. Major human monohydroxylated metabolites of JWH-018 and the related JWH-073 retain high affinity and act as potent agonists at CB2 receptors, and JWH-018 required less receptor occupancy than THC to inhibit adenylyl cyclase, indicating efficient receptor coupling.

This means its effects can be prolonged and intensified by metabolites rather than terminated by them. The human consequences are well documented and largely harmful. An exploratory study of psychiatric patients found that most users of a JWH-018-containing 'herbal incense' product experienced anxiety or psychotic symptoms, with the majority showing signs consistent with psychotic relapse.

In mice, JWH-018 and its halogenated derivatives impaired novel object recognition and disrupted hippocampal synaptic transmission and plasticity through CB1 receptors, matching the memory impairment seen in humans. Structure-activity reviews place JWH-018 as the prototype naphthoylindole whose scaffold spawned a wave of ever-changing designer cannabinoids that challenged forensic regulation. It has no accepted therapeutic use.

JWH-018 is hazardous and has no medical use. Reported effects include acute anxiety, agitation and psychosis, tachycardia, hypertension, seizures and vomiting, along with tolerance, dependence and withdrawal. Potency and contamination in 'Spice' and 'K2' products are unpredictable, compounding the risk. It is a controlled substance in most countries.

JWH-018 was synthesized in the laboratory of chemist John W. Huffman at Clemson University (the 'JWH' initials) as part of cannabinoid receptor research, and it emerged around 2008 as the original active ingredient in 'Spice' herbal incense before being scheduled.

It is infamous as a designer drug of abuse rather than any kind of nootropic or supplement, and is primarily discussed in forensic, toxicological and harm contexts.